{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:10:14Z","timestamp":1767852614730,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.molmed.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:15:19Z","timestamp":1717589719000},"page":"804-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Molecular therapy for polyQ disorders: from bench to clinical trials"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3755-3067","authenticated-orcid":false,"given":"Jo\u00e3o","family":"de Sousa-Louren\u00e7o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-5847","authenticated-orcid":false,"given":"Ana C.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5831-3307","authenticated-orcid":false,"given":"Lu\u00eds","family":"Pereira de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5816-2051","authenticated-orcid":false,"given":"Rui J.","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2024.05.004_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","article-title":"Polyglutamine repeats in neurodegenerative diseases","volume":"14","author":"Lieberman","year":"2019","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.molmed.2024.05.004_bb0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/brain\/awz328","article-title":"Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders","volume":"143","author":"Silva","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2024.05.004_bb0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd.2018.93","article-title":"Principles for targeting RNA with drug-like small molecules","volume":"17","author":"Warner","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2024.05.004_bb0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.molmed.2024.05.004_bb0025","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00401-020-02183-1","article-title":"Insulin-like growth factor 2 (IGF2) protects against Huntington\u2019s disease through the extracellular disposal of protein aggregates","volume":"140","author":"Garc\u00eda-Huerta","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.molmed.2024.05.004_bb0030","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/nat.2021.0020","article-title":"miRNA-mediated knockdown of ATXN3 alleviates molecular disease hallmarks in a mouse model for spinocerebellar ataxia type 3","volume":"32","author":"Nobre","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.molmed.2024.05.004_bb0035","unstructured":"Nobre, R.J. and Pereira de Almeida, L. University of Coimbra. (2020) Double stranded RNA and uses thereof, WO2020\/144611A1"},{"key":"10.1016\/j.molmed.2024.05.004_bb0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.omtm.2022.04.004","article-title":"Combined overexpression of ATXN1L and mutant ATXN1 knockdown by AAV rescue motor phenotypes and gene signatures in SCA1 mice","volume":"25","author":"Carrell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2024.05.004_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR\u2013Cas13d system alleviates disease-related phenotypes in Huntington\u2019s disease models","volume":"26","author":"Morelli","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.molmed.2024.05.004_bb0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41551-023-01007-3","article-title":"Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington\u2019s disease","volume":"7","author":"Yan","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.molmed.2024.05.004_bb0055","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ymthe.2023.04.001","article-title":"Extracellular vesicle-based delivery of silencing sequences for the treatment of Machado-Joseph disease\/spinocerebellar ataxia type 3","volume":"31","author":"Rufino-Ramos","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.05.004_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2021.02.007","article-title":"Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS","volume":"24","author":"Hirunagi","year":"2021","journal-title":"Nucleic Acids"},{"key":"10.1016\/j.molmed.2024.05.004_bb0065","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.ymthe.2024.02.033","article-title":"ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice","volume":"32","author":"Schuster","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2024.05.004_bb0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT\u2013LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424001266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424001266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T04:04:06Z","timestamp":1726373046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491424001266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1471491424001266"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2024.05.004","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular therapy for polyQ disorders: from bench to clinical trials","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}